KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) Gross Margin: 2010-2025

Historic Gross Margin for Pacira BioSciences (PCRX) over the last 16 years, with Sep 2025 value amounting to 80.91%.

  • Pacira BioSciences' Gross Margin rose 396.00% to 80.91% in Q3 2025 from the same period last year, while for Sep 2025 it was 79.17%, marking a year-over-year increase of 481.00%. This contributed to the annual value of 75.69% for FY2024, which is 305.00% up from last year.
  • Per Pacira BioSciences' latest filing, its Gross Margin stood at 80.91% for Q3 2025, which was up 4.48% from 77.43% recorded in Q2 2025.
  • Over the past 5 years, Pacira BioSciences' Gross Margin peaked at 80.91% during Q3 2025, and registered a low of 63.99% during Q4 2022.
  • For the 3-year period, Pacira BioSciences' Gross Margin averaged around 75.53%, with its median value being 75.75% (2023).
  • Its Gross Margin has fluctuated over the past 5 years, first tumbled by 1,150bps in 2022, then soared by 969bps in 2023.
  • Over the past 5 years, Pacira BioSciences' Gross Margin (MRQ) stood at 75.50% in 2021, then dropped by 15bps to 63.99% in 2022, then grew by 15bps to 73.69% in 2023, then increased by 7bps to 78.70% in 2024, then rose by 3bps to 80.91% in 2025.
  • Its Gross Margin was 80.91% in Q3 2025, compared to 77.43% in Q2 2025 and 79.69% in Q1 2025.